A Bortezomib-based Regimen Offers Promising Survival and Graft-vs.-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial

Hematopoietic stem cell transplantation (HSCT) recipients lacking HLA-matched related donors have increased graft-vs.-host disease (GVHD) and non-relapse mortality (NRM). Bortezomib added to reduced-intensity conditioning can offer benefit in T-replete HLA-mismatched HSCT, and may also benefit myelo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biol Blood Marrow Transplant
Autors principals: Koreth, John, Kim, Haesook T., Lange, Paulina B., Bindra, Bhavjot, Reynolds, Carol G., Chammas, Marie J., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Glotzbecker, Brett, Nikiforow, Sarah, Ritz, Jerome, Blazar, Bruce R., Soiffer, Robert J., Antin, Joseph H., Alyea, Edwin P.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4604028/
https://ncbi.nlm.nih.gov/pubmed/26055298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.05.027
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars